Immatics N.V. (IMTX)
NASDAQ: IMTX · IEX Real-Time Price · USD
10.21
-0.05 (-0.49%)
At close: Apr 19, 2024, 4:00 PM
10.11
-0.10 (-0.98%)
After-hours: Apr 19, 2024, 5:07 PM EDT

Company Description

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.

The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage.

The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial; and IMA403, which are in preclinical stages.

The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications.

Immatics N.V. is headquartered in Tübingen, Germany.

Immatics N.V.
Immatics logo
Country Germany
Industry Biotechnology
Sector Healthcare
Employees 535
CEO Dr. Harpreet Singh Ph.D.

Contact Details

Address:
Paul Ehrlich-strasse 15
Tubingen, 2M 72076
Germany
Phone 49 7071 5397 700
Website immatics.com

Stock Details

Ticker Symbol IMTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001809196
CUSIP Number N44445109
ISIN Number NL0015285941
SIC Code 2836

Key Executives

Name Position
Dr. Harpreet Singh Ph.D. Chief Executive Officer, MD, Member of Management Board and Executive Director
Dr. Toni Weinschenk Ph.D. Co-Founder and Chief Innovation Officer
Arnd Christ MBA Chief Financial Officer
Steffen Walter Ph.D. Chief Operations Officer
Edward A. Sturchio J.D. General Counsel and Secretary
Dr. Carsten Reinhardt M.D., Ph.D. Chief Development Officer
Cedrik M. Britten M.D. Chief Medical Officer
Jordan Silverstein Head of Strategy
Dr. Hans-Georg Rammensee Ph.D. Co-Founder and Member of the Scientific Advisory Board
Ephraim Hofsäß M.Sc. Vice President of SEC Reporting and Accounting

Latest SEC Filings

Date Type Title
Mar 21, 2024 6-K Report of foreign issuer
Mar 21, 2024 20-F Annual and transition report of foreign private issuers
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 22, 2024 6-K Report of foreign issuer
Jan 19, 2024 424B5 Filing
Jan 17, 2024 424B5 Filing
Nov 14, 2023 6-K Report of foreign issuer